Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 160

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

MSG-01: A Randomized, Double-Blind, Placebo-Controlled Trial of Caspofungin Prophylaxis Followed by Preemptive Therapy for Invasive Candidiasis in High-Risk Adults in the Critical Care Setting

Ostrosky-Zeichner, L., Shoham, S., Vazquez, J., Reboli, A., Betts, R., Barron, M. A., Schuster, M., Judson, M. A., Revankar, S. G., Caeiro, J. P., Mangino, J. E., Mushatt, D., Bedimo, R., Freifeld, A., Nguyen, M. H., Kauffman, C. A., Dismukes, W. E., Westfall, A. O., Deerman, J. B., Wood, C., Sobel, J. D., Pappas, P. G. · 2014 · Clinical Infectious Diseases

Abstract

BACKGROUND: Invasive candidiasis is the third most common bloodstream infection in the intensive care unit (ICU) and is associated with morbidity and mortality. Prophylaxis and preemptive therapy are attractive strategies for this setting. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial of caspofungin as antifungal prophylaxis in 222 adults who were in the ICU for at least 3 days, were ventilated, received antibiotics, had a central line, and had 1 additional risk factor (parenteral nutrition, dialysis, surgery, pancreatitis, systemic steroids, or other immunosuppressants). Subjects' (1,3)-β-d-glucan levels were monitored twice weekly. The primary endpoint was the incidence of proven or probable invasive candidiasis by EORTC/MSG criteria in patients who did not have disease at baseline. Patients who had invasive candidiasis were allowed to break the blind and receive preemptive therapy with caspofungin. The preemptive approach analysis included patients all patients who received study drug, including those positive at baseline. RESULTS: The incidence of proven/probable invasive candidiasis in the placebo and caspofungin arms was 16.7% (14/84) and 9.8% (10/102), respectively, for prophylaxis (P = .14), and 30.4% (31/102) and 18.8% (22/117), respectively, for the preemptive approach (P = .04); however, this analysis included patients with baseline disease. There were no significant differences in the secondary endpoints of mortality, antifungal use, or length of stay. There were no safety differences. CONCLUSIONS: Caspofungin was safe and tended to reduce the incidence of invasive candidiasis when used for prophylaxis, but the difference was not statistically significant. A preemptive therapy approach deserves further study. CLINICAL TRIALS REGISTRATION: NCT00520234.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/cid/ciu074

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 12

  1. 2003, Clinical Infectious Diseases, 37, 1172, 10.1086/378745 · DOI · Paper page
  2. 2004, Clinical Infectious Diseases, 39, S165, 10.1086/421951 · DOI
  3. Shorr, 2005, Critical care medicine, 33, 1928, 10.1097/01.CCM.0000178352.14703.49 · DOI · Paper page
  4. Ostrosky-Zeichner, 2004, Critical care medicine, 32, 2552, 10.1097/01.CCM.0000148226.95597.7E · DOI
  5. Garbino, 2002, Intensive care medicine, 28, 1708, 10.1007/s00134-002-1540-y · DOI · Paper page
  6. Pelz, 2001, Annals of surgery, 233, 542, 10.1097/00000658-200104000-00010 · DOI · Paper page
  7. 2006, Journal of Antimicrobial Chemotherapy, 57, 628, 10.1093/jac/dki491 · DOI · Paper page
  8. Ostrosky-Zeichner, 2011, Mycoses, 54, 46, 10.1111/j.1439-0507.2009.01756.x · DOI
  9. Ostrosky-Zeichner, 2007, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 26, 271, 10.1007/s10096-007-0270-z · DOI · Paper page
  10. 2011, Clinical Infectious Diseases, 52, 750, 10.1093/cid/ciq206 · DOI · Paper page
  11. Hanson, 2012, 7, e42282, 10.1371/journal.pone.0042282 · DOI
  12. Kartsonis, 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 6, 197, 10.1016/S1368-7646(03)00064-5 · DOI

Cited by

See all 160

Metadata

Authors
Ostrosky-Zeichner, L., Shoham, S., Vazquez, J., Reboli, A., Betts, R., Barron, M. A., Schuster, M., Judson, M. A., Revankar, S. G., Caeiro, J. P., Mangino, J. E., Mushatt, D., Bedimo, R., Freifeld, A., Nguyen, M. H., Kauffman, C. A., Dismukes, W. E., Westfall, A. O., Deerman, J. B., Wood, C., Sobel, J. D., & Pappas, P. G.
Venue
Clinical Infectious Diseases
Published
2014-02-18
Volume
58
Issue
9
Pages
1219-1226
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2135675030
Cited by
160
References
6
FWCI
15.79
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.